Cariprazine shows encouraging results in treatment of bipolar depression | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Cariprazine shows encouraging results in treatment of bipolar depression

Publication year - 2016

Publication title -

the brown university psychopharmacology update

Language(s) - English

Resource type - Journals

eISSN - 1556-7532

pISSN - 1068-5308

DOI - 10.1002/pu.30122

Subject(s) - confounding , placebo , bipolar disorder , depression (economics) , bipolar i disorder , antipsychotic , depressive symptoms , medicine , psychiatry , schizophrenia (object oriented programming) , psychology , anxiety , mood , alternative medicine , mania , pathology , economics , macroeconomics

A double‐blind, placebo‐controlled Phase II study of the atypical antipsychotic cariprazine for the treatment of bipolar depression has found the most highly effective outcomes with a dose of 1.5 mg/day. A dose of 3 mg/day resulted in improvement in depressive symptoms, but results were not significant when adjusted for potential confounding factors. A dose of 0.75 mg/day did not result in improvement over placebo. Results were published online Nov. 6, 2015, in the American Journal of Psychiatry .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research